KOR  ENG
  • IR

  • AbClon’s strong foundations and innovative platforms will help drive the future of
    personalized medicine and safeguard the health and hopes of families.

IR자료

제목 [NH투자증권] 하반기 R&D 모멘텀 유효
첨부파일 NH투자증권_구완성_20190722.pdf (786.6K) 날짜 2019-08-26 조회 690

1. 제목 : 하반기 R&D 모멘텀 유효

 

2. 기관명 : NH투자증권

 

3. 작성자 : 구완성 연구원

 

4. 분량 : 9page

 

5. 발간일 : 2019. 7.22

Designed by CHAIRONE
© AbClon. All rights reserved.